2m 2m 2m 2m 2m 2m 2m
- N/AMarket Cap
- -72.95%1-Year Change
- Drug Manufacturers - Specialty & GenericIndustry
Gelteq (GELS)
Key Performance
More- Earnings Score: N/A
- Momentum Score: 32
- True Yield: N/A
- Financial Health Score: N/A
Latest Research & News
U.S. stock futures declined on Wednesday as investors await a Supreme Court ruling on Trump's tariff authority. The Consumer Price Index rose 2.7% year-over-year in December, matching expectations, while core CPI came in slightly below forecasts at 2.6%. Major indices including the Dow Jones, S&P 500, and Nasdaq 100 all declined in premarket trading. Notable movers include Wells Fargo reporting earnings, BP announcing a $5 billion writedown in energy transition businesses, WeRide launching a robotaxi service on WeChat, and TG Therapeutics providing optimistic 2026 guidance.
01/14/2026, 8:36 AM • Benzinga
Peers
Statistics
MoreInformation as of 06/02/2026
Company Profile
Gelteq Limited focuses on developing and commercializing white label gel-based delivery solutions for humans and animals in the United States of America and Australia. It offers edible gels for prescription drugs, nutraceuticals, pet care, and other products, as well as for sports and over-the-counter products. Gelteq Limited was incorporated in 2017 and is headquartered in Clayton, Australia.
Key Executives
- Simon Hayden Szewach
- Bradley Glenn Karp
- Thuy-Linh Gigler
- Nathan Jacob Givoni
- Paul Wynne
Current Ownership Distribution
- Other7.7M (83.71%)
- Insiders1.5M (16.29%)
- Institutions0 (0.00%)
- Mutual Funds0 (0.00%)